Literature DB >> 19729888

MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma.

Gabriele Buda1, Alessandro Martino, Valentina Maggini, Enrico Orciuolo, Sara Galimberti, Massimo Gentile, Fortunato Morabito, Federica Antognoni, Marino Brunori, Roberto Barale, Anna Maria Rossi, Mario Petrini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19729888     DOI： 10.1159/000235820

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


× No keyword cloud information.
  3 in total

1.  Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.

Authors:  Gabriele Buda; Deborah Ricci; C Chris Huang; Reyna Favis; Nadine Cohen; Sen H Zhuang; Jean-Luc Harousseau; Pieter Sonneveld; Joan Bladé; Robert Z Orlowski
Journal:  Ann Hematol       Date:  2010-06-08       Impact factor: 3.673

2.  Association of ABCB1 polymorphisms and ulcerative colitis susceptibility.

Authors:  Yanju Cao; Changmin Qu; Yan Chen; Lianyong Li; Xiaoying Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy.

Authors:  Emily Foran; Deborah Y Kwon; Jonathan H Nofziger; Eveline S Arnold; Matthew D Hall; Kenneth H Fischbeck; Barrington G Burnett
Journal:  Neurobiol Dis       Date:  2016-01-11       Impact factor: 7.046
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.